Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nirmatrelvir/ritonavir is metabolised by CYP3A, and ritonavir is a strong inhibitor of CYP3A4. Daclatasvir exposure may be increased due to CYP3A4 inhibition but this is unlikely to be relevant considering the short duration of nirmatrelvir/ritonavir used for COVID-19 treatment. No dose adjustment is required.